These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 18194826)

  • 1. Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?
    You JH; Kei HW; Lau WC; Wong KY; Marasinghe T; Lee N; Ip M
    J Hosp Infect; 2008 Feb; 68(2):181-3. PubMed ID: 18194826
    [No Abstract]   [Full Text] [Related]  

  • 2. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
    Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
    J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addressing the challenge of extended-spectrum beta-lactamases.
    Zahar JR; Lortholary O; Martin C; Potel G; Plesiat P; Nordmann P
    Curr Opin Investig Drugs; 2009 Feb; 10(2):172-80. PubMed ID: 19197795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.
    Lagacé-Wiens PR; Nichol KA; Nicolle LE; DeCorby M; McCracken M; Mulvey MR; Zhanel GG
    J Antimicrob Chemother; 2006 Jun; 57(6):1262-3. PubMed ID: 16565157
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Metan G; Zarakolu P; Cakir B; Hascelik G; Uzun O
    Int J Antimicrob Agents; 2005 Sep; 26(3):254-7. PubMed ID: 16122910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community-acquired extended-spectrum beta-lactamase producers, United States.
    Doi Y; Adams J; O'Keefe A; Quereshi Z; Ewan L; Paterson DL
    Emerg Infect Dis; 2007 Jul; 13(7):1121-3. PubMed ID: 18214201
    [No Abstract]   [Full Text] [Related]  

  • 7. Refractory vertebral osteomyelitis due to CTX-M-14-producing Escherichia coli at ertapenem treatment in a patient with a coexisting urinary tract infection caused by the same pathogen.
    Lee CH; Su LH; Lin WC; Tang YF; Liu JW
    Int J Infect Dis; 2010 Sep; 14 Suppl 3():e183-6. PubMed ID: 19800278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Ena J; Arjona F; Martínez-Peinado C; López-Perezagua Mdel M; Amador C
    Urology; 2006 Dec; 68(6):1169-74. PubMed ID: 17169640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4.
    Peirano G; Pitout JD
    Int J Antimicrob Agents; 2010 Apr; 35(4):316-21. PubMed ID: 20060273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the beta-lactam resistance phenotypes of Escherichia coli. An 8-year survey conducted in Greece.
    Neonakis IK; Baritaki S; Georgiladakis A; Spandidos DA
    Roum Arch Microbiol Immunol; 2008; 67(1-2):10-3. PubMed ID: 19284160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial resistance in Escherichia coli outpatient urinary isolates from women: emerging multidrug resistance phenotypes.
    Ho PL; Wong RC; Yip KS; Loke SL; Leung MS; Mak GC; Chow FK; Tsang KW; Que TL;
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):439-45. PubMed ID: 17888610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Microbiol landscape and production of beta-lactamases with extended spectrum activity in patients with urinary tract infection].
    Zhevlakova IuA; Zakharova GV; Khokhlova OI; Ust'iantseva IM
    Klin Med (Mosk); 2009; 87(3):56-9. PubMed ID: 19469259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-spectrum beta-lactamases and clinical outcomes: current data.
    Ramphal R; Ambrose PG
    Clin Infect Dis; 2006 Apr; 42 Suppl 4():S164-72. PubMed ID: 16544267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predominance of CTX-M-15 extended spectrum beta-lactamases in diverse Escherichia coli and Klebsiella pneumoniae from hospital and community patients in Kuwait.
    Ensor VM; Jamal W; Rotimi VO; Evans JT; Hawkey PM
    Int J Antimicrob Agents; 2009 May; 33(5):487-9. PubMed ID: 19097760
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
    Hernández JR; Velasco C; Romero L; Martínez-Martínez L; Pascual A
    Int J Antimicrob Agents; 2006 Nov; 28(5):457-9. PubMed ID: 17008066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of carbapenems against a metallo-β-lactamase-producing Escherichia coli clinical isolate in a rabbit intra-abdominal abscess model.
    Souli M; Konstantinidou E; Tzepi I; Tsaganos T; Pefanis A; Chryssouli Z; Galani I; Giamarellos-Bourboulis E; Giamarellou H
    J Antimicrob Chemother; 2011 Mar; 66(3):611-7. PubMed ID: 21177674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-spectrum beta-lactamases in ambulatory care: a clinical perspective.
    Rodríguez-Baño J; Navarro MD
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():104-10. PubMed ID: 18154533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
    Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
    J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sensitivity to antibiotics of Escherichia coli strains isolated from children admitted to the "Sf. Ioan" clinical emergency hospital for children in Galaţi during 2005-2006].
    Florea C
    Bacteriol Virusol Parazitol Epidemiol; 2007; 52(1-2):37-44. PubMed ID: 18441957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Labombardi VJ; Rojtman A; Tran K
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):313-5. PubMed ID: 17084784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.